Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:CMNDNASDAQ:LPTXNASDAQ:LSB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.77-4.3%$1.84$1.23▼$4.84$16.67M0.77388,956 shs96,923 shsCMNDClearmind Medicine$1.03+1.0%$1.08$0.85▼$2.30$4.39M0.941.09 million shs34,097 shsLPTXLeap Therapeutics$0.40-1.1%$0.38$0.22▼$4.79$16.32M0.22821,259 shs512,398 shsLSBLakeshore Biopharma$1.24+1.6%$1.98$1.19▼$11.20$11.54M0.5820,854 shs18,080 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI0.00%+11.45%+8.82%-17.04%-36.43%CMNDClearmind Medicine0.00%-8.93%-4.67%-26.09%-12.07%LPTXLeap Therapeutics0.00%+10.04%+26.31%-82.23%-87.70%LSBLakeshore Biopharma0.00%-7.51%-51.39%-55.64%+121,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI0.3433 of 5 stars0.02.00.00.01.12.50.0CMNDClearmind Medicine1.1043 of 5 stars0.05.00.00.02.41.70.0LPTXLeap Therapeutics2.461 of 5 stars3.14.00.00.02.70.01.3LSBLakeshore Biopharma1.1714 of 5 stars0.05.00.00.02.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/ACMNDClearmind Medicine 0.00N/AN/AN/ALPTXLeap Therapeutics 2.25Hold$4.921,142.84% UpsideLSBLakeshore Biopharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CMND, LPTX, LSB, and BFRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral1/29/2025LPTXLeap TherapeuticsBaird R WSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold1/29/2025LPTXLeap TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral1/29/2025LPTXLeap TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$9.00 ➝ $1.25(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K277.74N/AN/A$0.43 per share4.12CMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/ALPTXLeap TherapeuticsN/AN/AN/AN/A$2.35 per shareN/ALSBLakeshore Biopharma$672.27M0.02N/AN/A$8.86 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%5/9/2025 (Estimated)CMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)LPTXLeap Therapeutics-$81.41M-$1.84N/AN/AN/AN/A-116.24%-93.18%5/12/2025 (Estimated)LSBLakeshore Biopharma-$61.09MN/A0.00∞N/AN/AN/AN/AN/ALatest CMND, LPTX, LSB, and BFRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025LPTXLeap Therapeutics-$0.38N/AN/AN/AN/AN/A3/26/2025Q4 2024LPTXLeap Therapeutics-$0.39-$0.37+$0.02-$0.37N/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/A3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/ACMNDClearmind MedicineN/AN/AN/AN/AN/ALPTXLeap TherapeuticsN/AN/AN/AN/AN/ALSBLakeshore BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90CMNDClearmind Medicine0.011.721.72LPTXLeap TherapeuticsN/A3.973.97LSBLakeshore Biopharma0.131.170.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%CMNDClearmind Medicine96.05%LPTXLeap Therapeutics30.46%LSBLakeshore Biopharma52.64%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%CMNDClearmind MedicineN/ALPTXLeap Therapeutics5.40%LSBLakeshore BiopharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableLPTXLeap Therapeutics4041.26 million36.25 millionOptionableLSBLakeshore Biopharma7739.31 millionN/AN/ACMND, LPTX, LSB, and BFRG HeadlinesRecent News About These CompaniesLakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)April 23, 2025 | prnewswire.comLSB Industries, Inc. Schedules 2024 Fourth Quarter and Full Year Financial Results Release for Wednesday, February 26th and Conference Call for Thursday, February 27thFebruary 6, 2025 | businesswire.comLakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial ApprovalDecember 19, 2024 | markets.businessinsider.comLakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year GuidanceDecember 19, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd: LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 13, 2024 | finanznachrichten.deLakeShore Biopharma Faces Challenges Amid Criminal Probe into Former ChairmanDecember 12, 2024 | markets.businessinsider.comLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaDecember 12, 2024 | globenewswire.comLakeShore Biopharma Co Ltd Ordinary SharesNovember 23, 2024 | morningstar.comLakeShore Biopharma Advances PIKA Rabies Vaccine ApprovalNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of PakistanNovember 8, 2024 | markets.businessinsider.comLakeShore Biopharma Announces Leadership TransitionNovember 2, 2024 | markets.businessinsider.comLakeShore Biopharma Achieves Nasdaq Compliance MilestoneOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma regains ompliance with Nasdaq minimum bid price requirementOctober 29, 2024 | markets.businessinsider.comLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 29, 2024 | prnewswire.comLakeShore Biopharma Advances with Rabies Vaccine TrialOctober 26, 2024 | markets.businessinsider.comLakeShore’s YSJA rabies vaccine receives approval for Phase III trial in ChinaOctober 26, 2024 | markets.businessinsider.comLakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies VaccineOctober 25, 2024 | prnewswire.comLakeShore Biopharma Shares Higher on Unchanged FY GuidanceOctober 10, 2024 | marketwatch.comLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial GuidanceOctober 8, 2024 | prnewswire.comLakeShore Biopharma Co., Ltd (H6Z.F)October 2, 2024 | au.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCMND, LPTX, LSB, and BFRG Company DescriptionsBullfrog AI NASDAQ:BFRG$1.77 -0.08 (-4.32%) Closing price 04:00 PM EasternExtended Trading$1.77 0.00 (0.00%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Clearmind Medicine NASDAQ:CMND$1.03 +0.01 (+0.98%) Closing price 03:59 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Leap Therapeutics NASDAQ:LPTX$0.40 0.00 (-1.08%) Closing price 04:00 PM EasternExtended Trading$0.39 -0.01 (-1.42%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Lakeshore Biopharma NASDAQ:LSB$1.24 +0.02 (+1.64%) Closing price 03:59 PM EasternExtended Trading$1.22 -0.02 (-1.61%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LakeShore Biopharma Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
